Depression: Early to late stage product analysis.
By Daniel Chancellor, Lead Analyst
21 November 2014
I am a Lead Analyst covering the CNS and rare disease markets at Datamonitor Healthcare. I joined in early 2010, having ...
Read full bio
With recent regulatory approvals depleting the late-stage pipeline for major depressive disorder (MDD), there is now an even higher barrier to market entry for novel candidates. Although reduced, the early-stage pipeline still has potential to improve upon current treatments, which are dominated by monoamine reuptake inhibitors.
Datamonitor Healthcare has reviewed the candidates in development for depression, highlighting key trends, analyzing clinical trial design and innovative early-stage projects, and hypothesizing on how future treatments may emerge.
How will our depression pipeline report benefit you?
- Identify early-phase opportunities
Access our exclusive interactive early-phase forecast model as well as an in-depth analysis of key modes of action, enabling you to identify any investment opportunities within the pipeline.
- Late-stage pipeline profiles
Evaluate the clinical development and commercial prospects for potential new antidepressant therapies in late-stage development, compared to those already on the market.
- Future of treatment
Understand how new research and development trends have the potential to change the current treatment paradigm and the challenges this has so far posed for the early-stage pipeline.
Key questions answered
- Will atypical antipsychotics be replaced as the primary adjunctive drugs in treatment-resistant depression?
- How will the dominance of generic selective serotonin reuptake inhibitors affect drug developers’ attempted positioning of novel treatments?
- What drugs have been recently discontinued and why?
|Drug List:||Companies Mentioned:|
Posted in Central Nervous System.